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Abstract
New psychoactive substances (NPS) continue to be considered as a major public health
concern in many European countries. The study was implemented within the framework of
a transnational project of six European countries (Germany, Hungary, Ireland, Netherlands,
Poland, Portugal). Our aim here is to report on the distinct and differentiating characteristics of
marginalised NPS users. Three subgroups of a total of 3023 adult NPS users (socially
marginalised, night life, online community) were examined regarding their socio-
demographic characteristics, substance use, and external motives towards NPS use. Poland
and Hungary reported higher rates of NPS use in comparison to traditional controlled drugs.
The external/contextual motives did not play a central role in the background of NPS use, the
least important motives were alleged legality and non-detectability of these substances.
Marginalised (defined as those accessing low threshold harm reduction services) users’
substance use patterns are different from the other two groups in terms of showing more
intense and riskier drug use. The most important variables which contributed to be categorised
as a marginalised NPS user were lower level education, being older, having an unfavourable
labour market position and using drugs intravenously. Contextual motives did not play a
decisive role in being categorised as a marginalised user when drug use pattern was controlled.
These identified discriminative features of marginalised drug users should inform policy
makers to develop and implement tailor-made interventions targeting this user group to
successfully tackle the elevated public health concerns associated with NPS use.
Keywords NPS use . User groups . Contextual motivation . Public health concern . Drug policy
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New psychoactive substances (NPS) are a major public health and policy concern in
several parts of the world. NPS are defined as “synthetic or naturally occurring sub-
stances that are not controlled under international law, and often produced with the
intention of mimicking the effects of controlled drugs” (EMCDDA 2014, p.27). In
general, NPS represent a multitude of synthetic and natural compounds marketed as
alternatives to conventional illicit drugs (i.e. cannabis, heroin, cocaine, speed, ecstasy),
the most popular being cathinone derivatives (i.e. mephedrone, 4-MEC, MDPV), other
amphetamine-type substances, and synthetic cannabinoids, with the phenomenon ob-
served since 2007 (Caudevilla 2016; EMCDDA 2016). The legislative procedures related
to NPS are very much varied in the different EU member states, covering, and initiating
a wide range of measures to tackle the problem. Neicun et al. (2019) concluded that in
most countries the general psychoactive substance-related legislation is in place to
establish a temporary or permanent ban on new psychoactive substances; the actual legal
consequences related to personal use (possession, cultivation, purchasing) of these
substances is depending on the general rigour or strictness of the penal code of the
given country.
The number of compounds labelled as NPS and observed through the Early Warning
System (EWS) of the EMCDDA has grown from 13 (in 2004) to 650 (in 2016). General
population-based prevalence estimates are rare and inconsistent with regard to trend
monitoring of NPS use (Korf et al. 2019). According to the Eurobarometer (telephone
surveys on drugs among young people aged 15–24 years in Europe), lifetime prevalence
of NPS use increased from 5 to 8% between 2011 and 2014 (Eurobarometer 2011 and
2014). The most recent ESPAD study in 2015 reported 4% life time and 3% last year
prevalence of NPS use among the 15–16-year-old European school population (ESPAD
group 2016), with large differences among the different countries. In England and Wales,
the 2010/2011 British Crime Survey identified a 0.6% lifetime ketamine use and 1.4%
lifetime mephedrone use (Smith and Flatley 2011). The 2015 National Survey on
Addiction Problems in Hungary found a 1.9%, 1.3% and 0.6% lifetime prevalence rate
for synthetic cannabinoids, designer stimulants and mephedrone, respectively (Paksi
et al. 2016). A national prevalence estimates among high-risk drug users in Belgium
showed that the average reported use was 26%, in case of synthetic cannabinoid receptor
agonists (SCRA) 19%, whilst for mephedrone 12.5% (European Monitoring Centre for
Drugs and Drug Addiction 2017a). In the Czech Republic, one-third of the high-risk
users had experience (LTP) with NPS (European Monitoring Centre for Drugs and Drug
Addiction 2017b). Surveys targeting special (vulnerable) populations of NPS use are rare
and struggle with methodological challenges; the available data suggest that these groups
are more prone to NPS use, and show higher prevalence rates across all NPS types
(MacLeod et al. 2016). Studies exploring the knowledge related to NPS in different
countries and age groups revealed that the relevant knowledge is unevenly distributed
among young respondents, with young people from rural areas showing less knowledge.
These studies also suggested that there is a strong association between NPS use and the
risk of binge drinking (Martinotti et al., 2015). The NPS situation has become even more
challenging due to the emerging synthetic opioid crisis, which seems to be less alerting
in most European countries than in the USA (Schifano et al. 2019); however, opiate use
and related death rates are also increasing in the EU countries. The synthetic opioids—
mostly fentanyl—play a significant role in those seeking specialised treatment in Europe
(EMCDDA 2018).
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Little knowledge is available about the specific motivations for NPS use and more
in-depth research is needed to better understand these reasons (Moore et al. 2013; Korf
et al. 2019). There are studies suggesting that the main motivations towards NPS use
are curiosity, the enjoyable effects, or enhancement of social situations, similar to other
conventional/classical drugs (Corazza et al. 2014; Measham et al. 2010; Werse and
Morgenstern 2012; Winstock et al. 2015). Studies which have assessed the motivational
background of NPS use have applied the four-factor motivation scale of Cooper (1994)
which is used to measure alcohol consumption motivations, and was later further
developed to measure cannabis (Simons et al. 1998) and amphetamine use related
motivations (Thurn et al. 2017). These motivation scales are based on the Cox and
Klinger’s Motivational Model (Cox and Klinger 1988) and concentrate on internal
motivations such as coping, curiosity, conformity and enhancement. The internal mo-
tivation of different user groups and the psychometric properties of a new motivation
scale appropriate for cross national study of NPS motivation were also analysed based
on the dataset of this research. Apart from identifying the psychometric properties and
usability of the scale in a transnational setting and in a special population, it was found
that marginalised users showed a higher endorsement in coping motives. The reported
results also suggest that marginalisation can be considered as a cross-cultural factor
behind instrumental substance use (Benschop et al. 2019 submitted). Studies assessing
contextual and/or external (pragmatic) motivations towards NPS use, revealed that
temporary legal status, easy availability, low price, high perceived or expected
quality/purity of these substances might play an important role in predicting use of
NPS (e.g., Werse and Morgenstern 2012; Barratt et al. 2013; Soussan et al. 2018;
Sutherland et al., 2017).
The aim of the present article is (i) to present some short term (last month, last year)
frequencies of substance use; (ii) to identify the role of external/contextual motivation
factors in NPS use of different user groups; and most importantly (iii) to identify a set of
variables (discriminating features) which might contribute to being categorised as
marginalised NPS user.
Methods
Sample
The work was undertaken as part of a large transnational interdisciplinary research
project (“New Psychoactive Substances: transnational project on different user groups,
user characteristics, extent and patterns of use, market dynamics, and best practices in
prevention” [NPS-t]) spanning six European countries (Germany, Hungary, Ireland,
Netherlands, Poland and Portugal). The data collection was carried out on a conve-
nience sample of three different user groups supposed to have diverging consumption
habits, motivations and socioeconomic background in both countries. Despite the high
number of respondents (N = 3023), none of our findings can be generalised for the
countries involved or for Europe as such. The survey was conducted between April and
November 2016. The different user groups reached have an uneven representation in
the sample; marginalised users proved to be hard to reach, mostly in Germany, the
Netherlands and Portugal.
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Three inclusion criteria were set as (1) recent NPS use (at least once in the past
12 months); (2) being resident of one of the participating countries; and (3) an age of
18 years or older. To reach the most heterogeneous sample of NPS users as possible,
three subgroups were aimed to examine (for more details see Van Hout et al. 2018; Korf
et al. 2019):
1. Socially marginalised users were defined by their (known and supposed) drug using
habits on one hand and by their availability (low threshold, harm reduction services)
and also by the venue of substance use, on the other. Marginalised users were
reported as using opioids, (crack) cocaine and or (meth) amphetamine—often and/
or frequently intravenously or through smoking. They were recruited and
interviewed face-to-face by trained fieldworkers or care professionals in the street,
or through care and treatment facilities (e.g., drug services, shelters) and through
snowball sampling;
In most cases the socially marginalised users were recruited from the capital of the participat-
ing country. The German marginalised sample consisted of, almost exclusively, persons from
the Munich scene, which is probably the only urban hard drugs users’ setting with substantial
(and mostly stimulant) NPS use in Germany.
2. Users in nightlife are recreational drug users who frequent clubs, raves and/or festi-
vals. They were mainly recruited face-to-face on-site at clubs, raves and festivals.
Users in night life mostly self-completed either a pen-and-paper or online question-
naire to which they were referred by a flyer containing a link and an individual code;
3. Users in online communities are users who are very active on the internet, and actively
participate in drug forums. They were recruited by posting messages on drug-related
social media and internet forums (i.e. eve-rave.ch/forum; www.legal-high-inhaltsstoffe.de;
www.daath.hu; www.drugs-forum.com; www.legalhighsforum.com). Users in online
communities were only given access to the online questionnaire.
Measures
The questionnaire contained items on demographics, routes of administration of sub-
stances, motives and frequencies of NPS and other drug use, social and health problems
related to it, modes of obtaining NPS, and possible perceived ways of tackling NPS
problems. Seven categories of NPS were initially included in the study based on their
epidemiological and clinical relevance: i.e., ‘herbal blends (e.g., ‘Spice’)’; ‘synthetic
cannabinoids (obtained pure)’; ‘branded stimulants (e.g., “bath salts”)’; ‘stimulants/
empathogens/nootropics (obtained pure, e.g., mephedrone, MDPV, a-PVP)’; ‘psyche-
delics (e.g., NBOMe-x, 2C-x’); ‘dissociatives (e.g., methoxetamine)’; and ‘other’.
However, survey responses indicated that participants were generally unable to either
properly categorise the NPS they had used or differentiate between certain categories
(i.e. between herbal blends and synthetic cannabinoids obtained pure and similarly
between branded stimulants and stimulants obtained pure) (Van Hout et al. 2018;
Korf et al. 2019). Therefore, these uncertain categories were merged into the following
categories: synthetic cannabinoids (including herbal blends names/ingredients); NPS
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stimulants (including bath salts and ingredients). In case of NPS dissociatives and NPS
psychedelics no merging of the categories was necessary. These NPS substance cate-
gories were used during the process of statistical analysis and throughout the presen-
tation of the results. The questionnaire also contained motivations related items1 to
investigate what were the most important reasons to use NPS. These questions had to
be answered on a 5-point Likert scale (1 = very unimportant; 5 = very important). The
items of the questionnaire were based on the Marijuana Motivation Scale (MMM,
Simons et al. 1998) and its further developed amended and psychometrically tested
version (Benschop et al. 2015). Six items reflecting external/contextual motives unique
for NPS use and not covered by the revised MMM were added: poor quality of other
(traditional) drugs, price, alleged legality, expecting different or new experiences
(regarding drug effects), non-detectability and low availability of other (traditional)
drugs.
Statistical Analysis
During the statistical analysis, SPSS 25.0 programme was used. Descriptive statistics
are presented on substance use frequencies and on external/contextual motives. Prin-
cipal component analysis was carried out on the external motivation items to assess if
these items construct a coherent scale. Variance analysis was carried out to assess the
differences regarding external/contextual motives in different user groups and/or coun-
tries, and finally, binary logistic regression models were developed to assess the
possible factors contributing to be categorised as a marginalised user.
Results
Descriptive Statistics—Sample Characteristics
The number of respondents reached in the different countries and user groups varied
significantly across the participating countries (see Table 1). The highest number of
marginalised users was recruited in Hungary, whilst the highest number of online users
was reached in the Netherlands. The most balanced sample (in number of respondents
belonging to the different user groups) was achieved in Poland. As there was no way to
carry out a probabilistic and random sample selection in these special populations none of
the samples were representative of the participating countries.
The sample was very much varied as far as the socio-demographic characteristics of the
respondents are concerned. Most of them were male, and lived in larger cities, the most
noticeable differences can be seen in the level of education (the lowest level education was
observed among marginalised users and the highest in the on-line community) and in the
employment conditions; most marginalised users were unemployed whilst night life and
online community representatives were either students or full-time workers (for further
details see Korf et al. 2019).
1 The current paper is not presenting findings on all motivation related items; it is focusing exclusively on the
newly added 6 items. The motivation scale without the newly added items (its psychometric properties and cross-
cultural usability) was analysed in another article (Benschop et al. 2019, submitted).
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Short Term (Last Month2) Frequency of Substance Use in Different User Groups
According to last month frequency of substance use, all user groups, regardless of their country
of residence, are also using controlled substances; apart from Hungary and Poland, these
frequencies are the highest in all user groups. Due to the fact that the different user groups were
reached in an uneven proportion in the different countries, the following results would describe
the short-term frequencies of substance use in different user groups. To be able to show the
problematic nature of substance use, frequencies of intravenous drug use were also included
into the analysis.
Marginalised Users
Last month frequency of controlled substance use is lower among marginalised users than in
the other two user groups (66.4% vs. above 80%). The most popular substances among new
psychoactive substances are the NPS stimulants and the synthetic cannabinoids. The highest
frequency of intravenous drug use was observed among this user group, half of them applied
this route of administration in the month preceding the data collection. NPS psychedelic use is
very rare among marginalised users, less than 6% of them used this type of substance in the
last month.
2 We deliberately chose last month frequency of use to present the differences among user groups and
countries. The inclusion criteria for all the respondents were NPS use at least once in the preceding
12 months; consequently, the measured last year frequency of use was considerably high in all user
groups. According to the recently introduced new “High Risk Drug Use Indicator” by the EMCDDA
(2013) this “…..indicator area focuses on “High-risk drug use”, “recurrent drug use that is causing actual
harms (negative consequences) to the person (including dependence, but also other health, psychological
or social problems) or is placing the person at a high probability/risk of suffering such harms. High risk
drug use is measured as the use of psychoactive substances by high risk pattern (e.g. intensively) and/or
by high risk routes of administration….” EMCDDA, 2013, p.3.). As the main objective of this paper is to
describe the discriminating features of marginalised users we wanted to capture the most visible elements
of high-risk drug use, among them short-term (last month) use (as recurrent and intensified drug use) and
the most harmful modes of administering substances (injecting).
Table 1 Composition of the sample according to countries and user groups (number and percentage of
respondents)
Marginalised Nightlife Online Total
Germany 23 (32.47%) 98 (14.78%) 542 (81.75%) 663
Hungary 101 (37%) 15 (5.51%) 156 (57.35%) 272
Ireland 48 (77.42%) 3 (4.84%) 11(17.74%) 62
The Netherlands 1(0.08%) 189 (17.04%) 1000 (90.17%) 1190
Poland 86 (17.43%) 172 (28.86%) 338 (56.71%) 596
Portugal 7 (2.92%) 170 (70.83%) 63 (26.25%) 240
TOTAL 266 (8.80%) 647 (21.40%) 2.110 (69.80%) 3.023
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Users in Night Life
Controlled substances are the most prevalent substances in the night life user group
(84.5%) as well, the second most prevalent substances in this user group are NPS
stimulants and NPS psychedelics (25% and 20.1%, respectively). Synthetic cannabi-
noids are also popular in this user group as every 9th respondents used this substance
during the month before the data collection was carried out. Almost no intravenous
drug use can be observed in this user group (1.40%).
Users in Online Community
In the online NPS user group, after the most prevalent controlled substances, NPS
stimulants rank second and NPS psychedelics the third place (43% and 17%, respective-
ly). Synthetic cannabinoids are the fourth most popular NPS substance used in this group
during the month preceding the data collection. Last month frequency of intravenous
drug use is low, 1.20% in this user group (Table 2).
Short-term frequencies of substance use show that NPS users do not form an independent
group of substance users, traditional controlled substances still play a significant role in the
poly-substance use patterns of NPS users. The last month frequencies of substance use,
especially when we compare them with data stemming from general adult population surveys
of the last 3 years, show that recent NPS users in the current sample are very intensive
substance users. The frequencies of substance use estimates suggest that the most popular new
psychoactive substances (synthetic cannabinoids, NPS stimulants) are 2–3 times more fre-
quently used monthly among recent NPS consumers (the frequencies are between 33.80 and
45.50%) than any controlled substances in the general population of the same countries. For
the most popular substances (cannabis and MDMA) the highest prevalence was 15.70% and
9.20% respectively (EMCDDA 2018). However, not just NPS are used heavily among recent
NPS users, but the last month frequencies of substance use for all controlled substances is four
to five times higher among recent NPS users than in the general population, as it is presented in
the European Drug Report (EMCDDA 2018).
Table 2 Last month frequencies of substance use (%) according to user groups
User groups Marginalised N = 266 Night life N = 647 Internet N = 2110 χ2 (p)
Substance categories
Synthetic cannabinoids, N(%) 90 (33.8)a 78 (12.1)b 243 (11.5)b 101.8***
NPS stimulants N(%) 121 (45.50)a 162 (25.00)b 914 (43.30)a 73.4***
NPS psychedelics N(%) 15 (5.60)a 130 (20.10)b 366 (17.30)b 29.0***
NPS dissociatives N(%) 16 (6.00)a 21 (3.20)a 118 (5.60)a 6.1*
All controlled substances N(%) 174 (66.40)a 533 (84.50)b 1712 (81.60)a 41.5***
Intravenous drug use N(%) 133 (50.00)a 9 (1.40)b 26 (1.20)b 1084.1***
Synthetic cannabinoids included synthetic cannabinoids pure, herbal brands; NPS stimulants included branded
stimulants (e.g. “bath salts”), empathogens, nootropics, (obtained pure, e.g.. mephedrone, MDPV, a-PVP); NPS
Psychedelics included e.g. NBOMe-x. 2C-x′; NPS dissociatives included, e.g. methoxetamine; controlled
substances included cannabis, amphetamine, xtc, cocaine, crack-cocaine, heroin, magic mushroom, LSD,
metamphetamine, ketamin, GHB. *p < 0.05; ***p < 0.001. Different subscript letters indicate a significant (p ≤
0.05) differences in proportions
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Perceived Context of NPS Use among Different User Groups
The focus of our current analysis regardingmotives was to find out if the external/pragmatic items
added to the motivation scale can deepen our understanding regarding the motivation towards
NPS use. The mean scores of the sample show that these external/contextual motives were rated
3.1 or less on the five-grade Likert scale. Items related to the legal status and to the perceived non-
detectability of NPS were given ratings lower than 2. There are considerable differences among
user groups; in general, marginalised users rate these items higher (consider themmore important)
than the other user groups with the only exception of “Expecting different or new experiences
(regarding drug effects)”. This item is rated highest among night life users (see Table 3).
Even though the analysis found relatively low ratings of external/contextual motives towards
NPS use, during the next step, for methodological clarity, we studied if the newly included
items of the motivation scale construct a coherent factor to measure external/contextual
motivations towards NPS use. The principal component analysis on these items extracted only
one component with the following items: ‘alleged legality’, ‘price’, ‘low availability of other
(traditional) drugs’, ‘non-detectability’ and ‘poor quality of other (traditional) drugs’ whilst
‘expecting different or new experiences (regarding drug effects)’ did not become part of this
factor. The identified factor was able to explainmore than 44% of the variances. The component
loadings ranged between 0.60 and 0.73. This factor was given the contextual motivation factor
label. The Cronbach Alpha for these items was 0.682, which is on the threshold of acceptability.
As the main focus of the present analysis is to identify the discriminative features of
marginalised users compared to other user groups, we analysed the variances of the external/
contextual motivation factor scores in marginalised and non-marginalised users across the
different countries. To be able to do so, we applied a re-coding during which we kept the
marginalised group as it was (N = 265), and the night life and online community groups were
merged into one variable labelled as non-marginalised (N = 1568). The Netherlands was left out
from this analysis as only one marginalised respondent was interviewed in this country.
As the figure below (Fig. 1) shows, contextual/external motivation factor scores are higher
among marginalised users in all countries included into the analysis, whilst in two countries
Table 3 The variance of contextual motives among user groups
Motives User groups Statistics
Marginalised N =
266
Night life N =
647
Internet N =
2110
F*
Alleged legality, mean (SD) 1.79 (1.26)a 1.36 (0.84)b 1.57 (1.16)c 14.93***
Poor quality of other traditional drugs,
Mean (SD)
2.45 (1.58)a 1.48 (0.94)b 1.78 (1.26)c 53.34***
Price, mean (SD) 2.46 (1.64)a 1.53 (1.08)b 1.81 (1.24)c 47.60***
Expecting new experiences, mean (SD) 2.55 (1.51)a 3.08 (1.54)b 2.79 (1.53)a 13.2***
Non-detectability, mean (SD) 1.94 (1.42)a 1.31 (0.94)b 1.50 (1.12)c 28.70***
Lack of traditional drugs, mean (SD) 2.35 (1.52)a 1.44 (0.92)b 1.77 (1.31)c 47.05***
Contextual motive scale, mean (SD) 2.23 (0.96)a 1.49 (0.70)b 1.91 (0.91)c 75.720***
*ANOVA
***p < 0.001
The Games-Howell test was used as post hoc test. Different subscript letters indicate a significant difference (p ≤
0.05) in the parameters
Contextual motive scale results are presented without the Netherlands, the N for the user groups is marginalised,
265; night life, 458; Internet 1110
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(Hungary and Poland), the differences in the means between marginalised and non-
marginalised user groups are much smaller than in the others. These comparisons show that
contextual motivations presumed to be NPS specific play a different role depending on the
country of residence of the respondents.
Discriminating Features of Marginalised NPS Use—Binary Logistic Regression
In the next phase, we studied the factors that might describe the discriminating features of
marginalised NPS users. For this purpose, two binary logistic regression models were created;
in each case, the dependent variable was if the respondent was categorised as marginalised vs.
non-marginalised user. The Netherlands was left out from this analysis as the total number of
marginalised users reached during the interview was only one person. The total number of
respondents included into this analysis was 1833. In the first model, we included only socio-
demographic characteristics (education, current status of employment, gender, age, size of the
settlement and living conditions). The low level of accomplished education, living on benefits,
being unemployed, being older, living with friends, using homeless-type accommodation
arrangements and living in bigger settlements significantly increased the probability of being
a marginalised user (see Table 4).
Country of residence seems to be associated with significant and high odds ratios for being
categorised as a marginalised user, though these findings might just be the consequence of sample
attainment. As the number of marginalised users reached during the data collection was very
much varied we carried out a country based binary logistic regression analysis as well during
which the same set of variables were used to find out the country specific characteristics of the
marginalised user group. Level of education played a role in being categorised as a marginalised
user in the case of Hungary and Germany. In Hungary, less education elevated the risk of being
part of the marginalised user group whilst in Germany any accomplished education increased this
risk (very probably due to the high number of participants with higher education attainment in the
sample). The employment status proved to be an active ingredient of being categorised as a
marginalised user in Poland. Living on benefits or being unemployed elevated this risk 32–9.2
times higher than being a student. Age also had a different role depending on the country of
1.00
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Fig. 1 The variance of contextual motivation according to user groups and countries (N = 1801). Note: F value
for countries, 5.811***; for user groups, 16.343***; for country*user group interaction, 1.612, *** p < 0.001
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residence of the respondent. In case of Hungary and Poland, being older than 24 highly elevates
the risk of being part of the marginalised group. Living with friends just in Germany, residential
care in Germany and Poland and homeless accommodation in Germany, Hungary and Poland
contributed to the marginalised categorisation. Size of the settlement where the respondent was
living did not add to this categorisation. In the case of Portugal and Ireland, none of the variables
revealed any patterns (see detailed result in Appendix Table 6).
Another binary logistic regression model was developed on substance use–related behav-
iour (Table 5). We included NPS and controlled substance use frequencies (life time, last year,
last month), venue of substance use, problems (physical, social and mental health) experienced
after using NPS, parallel usage of different substances, and contextual motivation factor. The
model shows that characteristics of problem drug use (EMCDDA, 2009) are clearly associated
with being a marginalised respondent. Those who used heroin or methamphetamine during
Table 4 Binary logistic regression analysis of socio-demographic factors for being categorised as a marginalised
user
Variables OR (95% C.I.) p
Country of residence
Hungary 46.71 (16.80–129.84) < 0.001
Ireland 72.00 (16.78–308.92) < 0.001
Portugal 4.56 (1.38–14.99) 0.012
Poland 19.09 (7.56–48.21) < 0.001
Germany Ref.
Level of education
None 26.26 (1.83–377.20) 0.016
Primary school 9.72 (1.17–80.88) 0.035
Secondary school 1.91 (0.24–15.32) 0.541
College 0.49 (0.06–4.09) 0.508
MA or higher Ref.
Current status of employment
Full-time worker 0.84 (0.25–2.75) 0.768
Part-time worker 1.70 (0.59–4.90) 0.326
Self-employed 1.16 (0.32–4.17) 0.825
Benefits 12.47 (3.88–40.08) < 0.001
Retired 2.61 (0.19–35.28) 0.471
Home duties 8.14 (0.51–129.14) 0.137
Unemployed 4.05 (1.53–10.73) 0.004
Other 0.69 (0.02–25.91) 0.841
Student Ref.
Age categories
18–24 Ref.
25–34 3.32 (1.64–6.72) < 0.001
35–44 7.96 (3.19–19.88) < 0.001
45– 16.56 (4.41–62.14) < 0.001
Living conditions
Own home Ref.
With parents/family 1.80 (0.72–4.62) 0.201
With friends/in friends’ home 13.15 (3.80–45.53) < 0.001
Residential care 64.34 (16.01–258.58) < 0.001
Rent apartment or room 1.48 (0.59–3.70) 0.403
Homeless accommodation/hostel 81.60 (18.94–351.66) < 0.001
Other 31.36 (6.29–156.43) < 0.001
Size of the settlement
Below 50,000 Ref.
Between 50 and 100,000 4.30 (1.46–12.64) 0.008
More than 100,000 8.43 (3.49–20.35) < 0.001
Ref., Reference category
Binary logistic regression analysis (FSTEP), 8 iterations
All variables remained in the equation, though just a few of them contributed significantly to the categorisation
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their life time or in the last year have a 2.1 to 3.1 times bigger chance to be categorised as
marginalised than those who did not. In case of those who had ever or during the last year
injected any kind of substances, the odds ratios are considerably elevated. Frequencies of
current substance use reveal that using synthetic cannabinoids or crack also highly increases
the odds ratios for being categorised as marginalised user, whilst using cannabis or amphet-
amine during the last month decreased the chance for belonging to this category. If someone is
using substances in residential care, the chance for being categorised as a marginalised user is
5.4 times higher, whilst using NPS and alcohol or controlled substances together decreases the
likelihood of being categorised as a marginalised user.
As we found considerable differences in the sociodemographic variables according to
countries of residence, we analysed the country-specific contributing factors of substance
Table 5 Binary logistic regression analysis of substance use related factors for being categorised as a
marginalised user
Name of the variable OR (95% C.I. ) p.
Last year/life time substance use
Last year NPS psychedelic use 0.25 (0.13–0.47) < 0.001
Last year ecstasy use 0.60 (0.34–1.03) 0.066
Life time heroin use 2.06 (1.10—3.85) 0.023
Last year methamphetamine use 3.09 (1.70–5.59) < 0.001
Last year LSD use 0.41 (0.19–0.85) 0.017
Life time intravenous drug use 8.32 (4.28–16.20) < 0.001
Last month substance use
Last month synthetic cannabinoids use (incl. all herbal blends) 2.28 (1.38–3.77) 0.001
Last month cannabis use 0.37 (0.23–0.59) < 0.001
Last month amphetamine use 0.40 (0.21–0.77) 0.006
Last month crack use 6.93 (2.18–22.05) 0.001
Last month intravenous drug use 5.22 (2.52–10.81) < 0.001
Problems and risk behaviour
Perceived social problems 0.48 (0.30–0.76) 0.002
NPS consumption together with controlled substances 0.54 (0.34–0.85) 0.008
NPS consumption together with alcohol 0.49 (0.31–0.77) 0.002
Venue of consumption
At own home 0.24 (0.15–0.39) < 0.001
At a friend’s house 0.57 (0.35–0.91) 0.018
Night life 0.57 (0. 34–0.95) 0.029
In residential care 5.42 (1.62–18.09) 0.006
Ref., reference category
Binary logistic regression analysis (FSTEP), 7 iterations
Synthetic cannabinoids included synthetic cannabinoids pure. Herbal brands; NPS stimulants included branded
stimulants (e.g.: “bath salts”), empathogens, nootropics (obtained pure, e.g.: mephedrone. MDPV, a-PVP), NPS
psychedelics included, e.g. NBOMe-x. 2C-x′, NPS dissociatives included, e.g. methoxetamine; controlled
substances included cannabis, amphetamine, xtc, cocaine, crack-cocaine, heroin, magic mushroom, LSD,
metamphetamine, ketamin, GHB
Variables not remained in the equation during the FSTEP procedure:
Substance use related variables: synthetic cannabinoids last year consumption; stimulants/empathogens/
nootropics pure last year and last month consumption; dissociative last year and last month consumption,
psychedelics last month consumption, cannabis las year consumption, cocaine last year, last month consumption,
heroine last year, last month consumption, crack last year consumption, LSD last month consumption,
metamphetamine last month consumption, NPS use together with another NPS
Venue of the substance use related items: work place, special places created for drug users
Contextual motive scale
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use (the same set of variables as described above) in being categorised as a marginalised user.
(see Appendix, Table 7). The analysis revealed that last year and last month use of heroin and
intravenous drug use (in Germany and Poland), amphetamine, methamphetamine use (in
Poland) and synthetic cannabinoid and crack use (in Hungary), highly elevated the risk of
being categorised as a marginalised user. The parallel use of different new substances (NPS)
contributed to being categorised as a marginalised user in Germany (OR = 6.53), whilst the
venue of substance use found to be influential in the case of Poland where usage in residential
care substantially increased the odds ratios of this type of categorisation. Contextual motives
did not contribute to being categorised as a marginalised user among German respondents. In
the case of Portugal and Ireland none of the variables revealed any patterns, probably due to
the low sample size reached in these countries.
Discussion
The study has provided unique insight into NPS and controlled drug using patterns of different
user groups and identified a series of demographic and external contextual factors potentially
contributing to being categorised as marginalised user in six European countries. Based on
frequencies, and mostly on short-term frequencies of substance use (last month) we can say that
among recent NPS users, much higher frequencies of substance use can be observed than in adult
population surveys, suggesting that we studied a very specific population. The special nature of
the population we studied was illustrated in the results chapter, based on comparing our own data
and the ones presented in the 2018 European Drug Report (EMCDDA 2018). Based on this
comparison, it can be assumed that those three user groups which were investigated in the context
of a large European transnational project are much more intense, and in some cases, much more
problematic users than those representing the adult population in the relevant countries. The
impression of intense substance use in these groups might also be the consequence of poly drug
using tendencies of NPS users; NPS use very frequently happens in the context of polysubstance
use (European Monitoring Centre for Drugs and Drug Addiction 2017b). The problematic nature
of substance use is supported by the frequent intravenous substance use especially among
marginalised users. Another warning sign is that the respondents were not necessarily able to
say what kind of substance they were using, and they were not able to reflect on the active
ingredients of the substances (see further details in Van Hout et al. 2018; Korf et al. 2019).
Epidemiological research so far has not yet revealed the discriminating features of different
NPS user groups as large-scale representative studies cannot reflect on the specificities of
special groups. There are plenty of studies which describe the socioeconomic properties of
substance users (including legal and illegal substances); these studies consistently claim that
disadvantageous socioeconomic situation significantly contributes to elevated risk of heavy/
problematic substance use (see e.g. Janicijevic et al. 2017). In the light of the few adult
population surveys implemented in the last few years, it can be assumed that NPS play a
substantial role in the poly-consumption patterns of drug users (i.e. Paksi et al. 2016, 2017).
According to our analysis and in accordance with other studies (i.e. Van Hout et al. 2018),
the substance-related preferences of different user groups vary. In all user groups (marginalised
users, night life and online), the most frequently used substances are the controlled ones, with
NPS being just part of poly-substance using repertoires. Based on our data and in accordance
with other research (Potter and Chattwin 2018), it can be said that NPS use does not constitute
an independent category of drug use; NPS users are still using controlled substances, though
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marginalised users are using significantly less of them than the other user groups. In the case of
marginalised users, regardless of their country of residence, the rates for current use show that
NPS play a relatively bigger role in their drug using preferences than traditional controlled
substances, which is the reverse in the case of other user groups (night life and internet
community). The most popular NPS type substances among marginalised users are synthetic
cannabinoids, and NPS stimulants. In some countries, it is worth noting, as qualitative research
also revealed (Kaló et al. 2017), that some individuals in disadvantageous social-economic
situations start drug-using careers or pathways with NPS. The early onset of psychoactive
substance use and especially the preference towards NPS, contributes substantially to the
development of particularly destructive forms of drug use in socially marginalised groups.
Our analysis also revealed that the newly added items to the motivation scale are organised
in one factor named contextual factor. The analysis also revealed that the perceived (reported)
importance of these motives do not play a decisive role in drug using preferences of recent
NPS users. We can conclude that, if at all, particularly low availability and poor quality of
controlled substances as well as the relatively low price of NPS may play a more important
role in the motivation towards these substances in case of marginalised users compared with
other recent NPS user groups. The respondents from all user groups rated the contextual
motivation items relatively low, the least important motives are the alleged legality and non-
detectability of these substances. The relative unimportance of these items might be the
consequence of the legal status of different new psychoactive substances in the different
countries. Another possible explanation of this finding might also be that all recent NPS users
are (intensively) using controlled substances; consequently, the temporary legal status of any
given NPS is not a significant issue to articulate their choices for consumption. This finding
might be highly relevant in the drug policy/legislation debates in connection to the current
regulatory efforts. Some of the external/contextual motivation items received higher ratings
from marginalised respondents with significant differences depending on country of residence.
Data describing the drug use patterns of the three diverse NPS user groups and the
regression model, including a wide range of socio-demographic variables (age, level of
education, labour market position, recent use of NPS and controlled substances, route of
administration), strongly suggest that marginalised users are the most at-risk population with
lower education and with the most risky drug using patterns. As our selection criteria regarding
marginalised users was very much concentrating on the venue of substance use (streets, public
places) and/or being clients of low threshold/harm reduction services and their networks, it is
very much reassuring that our analysis revealed that the marginalised users reached have
indeed a well identifiable socio-demographic profile, describing their elevated vulnerability.
These findings not just mirror the sample selection criteria, but it draws a more refined picture
regarding the socio-demographic factors and the discriminating substance use habits of
marginalised users; outlining the profile of high-risk problematic drug use.
The binary logistic regression model, which included all respondents from the participating
countries (apart from the Netherlands) is conclusive regarding the main sociodemographic
characteristics and substance use patterns of the marginalised user group. More detailed
country-based analysis suggests that variables supposed to be contributing to the
marginalised—non-marginalised categorisation of the respondents in different countries are
very much varied, at some points, the findings are even contradictory. Therefore, it is
suggested that further epidemiological studies should be carried out to obtain reliable data
from different countries on the relative weight of NPS use in different user groups and on other
factors contributing to enhance our user group specific understanding of NPS use and, in
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general, problematic drug use behaviour. Further research is especially needed as our data
cannot be considered as representative for the participating countries or for the chosen user
groups. Contextual motives, as the logistic regression model shows, do not contribute to be
categorised as a marginalised user when other variables were controlled. The intense drug use
of marginalised NPS users should call the attention of policy makers to strengthen tailor-made
harm reduction services and targeted prevention activities in these groups, to properly respond
to the public health and legal concerns in some European countries where NPS use is
especially prevalent among low social status marginalised users.
Conclusions
This study contributes to the better understanding of NPS use in special populations, especially
in the marginalised user group, by describing the discriminating features of substance use, its
setting and the sociodemographic properties of respondents in this group. This statement might
remain to be true even though the data collection was carried out on a convenience sample
(with different but standardised recruitment strategies in each user group) and the number of
respondents in the different user groups was very much uneven, and we have no sufficient
reliable information on the prevalence of NPS use in the general population. Our data can
inform decision-makers about the necessity of enhancing complex interventions targeting high
risk marginalised users and also the scientific community that large-scale epidemiological
surveys in special populations should be carried out to further develop our understanding
regarding NPS use in certain populations.
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